Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
July 15, 2021 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy...
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK
December 30, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”...
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
November 23, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19 Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the...
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director
November 23, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and...
Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
October 06, 2020 07:48 ET
|
Oxford BioMedica plc
Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB)...
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics
August 03, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics Oxford, UK – 3 August...
Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD
July 31, 2020 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD Oxford, UK – 31st July, 2020: Oxford Biomedica plc...
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
June 08, 2020 07:00 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
May 28, 2020 07:38 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Interim Results
September 04, 2019 07:00 ET
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell...